AC Immune First Quarter 2026 Financial and Corporate Updates
AC Immune First Quarter 2026 Financial and Corporate Updates * Dosed first subjects in Phase 1 trial of brain-penetrant small molecule NLRP3 inhibitor ACI-19764 with SAD/MAD results in healthy volunteers expected in H2 2026 * Initiated final cohort, AD4, in ABATE Phase 1b/2 trial of ACI-24 to treat Alzheimer's Disease triggers milestone payment, as announced separately today (https://ir.acimmune.com/news) * Amended Morphomer(®) Tau collaboration with Lilly reflects growing excitement for targeti
Globe Newswire ·